Health Canada Authorizes DAYVIGO™ (lemborexant)
Share this article Now available in Canada for the treatment of insomnia in adults MISSISSAUGA, ON, Feb. 4, 2021 /CNW/ - Eisai Limited, the Canadian subsidiary of Eisai Inc., today announced the Canadian authorization and availability of a new non-sedative prescription medication, DAYVIGO™ (lemborexant). Available in both 5 mg and 10 mg dosages, DAYVIGO is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and / or sleep maintenance. 1 DAYVIGO is now ava...
Eileen Tobey Pat Forsythe Charles Morin Research Centre At Universit University Of Alberta Eisai Rd Management Co Ltd
Source: newswire.ca